Dogwood Therapeutics, Inc. (DWTX) jumped 34.78 percent to $7.44 on Monday, up $1.92, after announcing it secured a royalty-free, global license to develop Serpin Pharma's IV formulation of SP16 for managing cancer-related pain and chemotherapy-induced neuropathy. The forthcoming Phase 1b trial of SP16 IV is fully funded by the National Cancer Institute. The stock opened at $8.41 and traded between $7.07 and $9.50, compared with a previous close of $5.52 on the Nasdaq. Trading volume surged to 41.7 million shares, well above the average of 19,600. The stock now trades within a 52-week range of $1.62 to $29.28.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.